Altimmune (ALT) Operating Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Operating Expenses data on file, last reported at $24.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 11.11% year-over-year to $24.2 million in Q1 2026; TTM through Mar 2026 was $97.0 million, a 1.28% decrease from a year earlier, with the FY2025 full-year figure at $94.5 million, down 8.39% from the prior year.
• Operating Expenses for Q1 2026 stood at $24.2 million, down from $28.9 million in the prior quarter.
• Over the last five years, Operating Expenses for ALT reached as high as $33.7 million in Q4 2023 and fell as low as $18.0 million in Q2 2023.
• Historically, Operating Expenses has averaged $23.9 million across 5 years, with a median of $23.0 million in 2022.
• On a YoY basis, Operating Expenses climbed as much as 48.5% in 2024 and fell as far as 26.11% in 2024.
• Year by year, Operating Expenses stood at $23.0 million in 2022, then soared by 46.45% to $33.7 million in 2023, then dropped by 26.11% to $24.9 million in 2024, then grew by 16.28% to $28.9 million in 2025, then slipped by 16.17% to $24.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $24.2 million in Q1 2026, $28.9 million in Q4 2025, and $20.9 million in Q3 2025.